Evidence map›Paper›PMID 39075558›Full record

ArticleBMC biology2024

Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling.

Ernesto Lopes Pinheiro-Junior, Ehsan Alirahimi, Steve Peigneur, Jörg Isensee, Susanne Schiffmann, Pelin Erkoc, Robert Fürst, Andreas Vilcinskas, Tobias Sennoner, Ivan Koludarov and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ernesto Lopes Pinheiro-Junior *Toxicology and Pharmacology - Campus Gasthuisberg, University of Leuven (KU Leuven), Herestraat 49, PO Box 922, 3000, Louvain, Belgium.
Ehsan Alirahimi *Department of Anesthesiology and Intensive Care Medicine, University Cologne, Translational Pain Research, University Hospital of Cologne, Cologne, Germany.
Steve PeigneurToxicology and Pharmacology - Campus Gasthuisberg, University of Leuven (KU Leuven), Herestraat 49, PO Box 922, 3000, Louvain, Belgium.
Jörg IsenseeDepartment of Anesthesiology and Intensive Care Medicine, University Cologne, Translational Pain Research, University Hospital of Cologne, Cologne, Germany.
Susanne SchiffmannFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596, Frankfurt Am Main, Germany.
Pelin ErkocInstitute of Pharmaceutical Biology, Goethe University Frankfurt, Max-Von-Laue-Str. 9, 60438, Frankfurt, Germany.
Robert FürstInstitute of Pharmaceutical Biology, Goethe University Frankfurt, Max-Von-Laue-Str. 9, 60438, Frankfurt, Germany.
Andreas VilcinskasLOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Senckenberganlage 25, 60325, Frankfurt, Germany.
Tobias SennonerDepartment of Informatics, Bioinformatics and Computational Biology, i12, Technical University of Munich, Boltzmannstr. 3, 85748, Garching, Munich, Germany.
Ivan KoludarovDepartment of Informatics, Bioinformatics and Computational Biology, i12, Technical University of Munich, Boltzmannstr. 3, 85748, Garching, Munich, Germany.
Benjamin-Florian HempelFreie Unveristät Berlin, Veterinary Centre for Resistance Research (TZR), Robert-Von-Ostertag Str. 8, 14163, Berlin, Germany.
Jan TytgatToxicology and Pharmacology - Campus Gasthuisberg, University of Leuven (KU Leuven), Herestraat 49, PO Box 922, 3000, Louvain, Belgium.
Tim HuchoDepartment of Anesthesiology and Intensive Care Medicine, University Cologne, Translational Pain Research, University Hospital of Cologne, Cologne, Germany.
Björn M von ReumontLOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Senckenberganlage 25, 60325, Frankfurt, Germany. bmvr@reumont.net.ORCID http://orcid.org/0000-0002-7462-8226

Funding

EU COST Action CA19144 EUVENF.W.O.-Vlaanderen G0E7120NF.W.O.-Vlaanderen GOA4919 NF.W.O.-Vlaanderen GOC2319 NKU Leuven funding PDM/19/164São Paulo Research Foundation 2016/04761-4
6 · The paper itself

Abstract

backgroundThe identification of novel toxins from overlooked and taxonomically exceptional species bears potential for various pharmacological applications. The remipede Xibalbanus tulumensis, an underwater cave-dwelling crustacean, is the only crustacean for which a venom system has been described. Its venom contains several xibalbin peptides that have an inhibitor cysteine knot (ICK) scaffold.

resultsOur screenings revealed that all tested xibalbin variants particularly inhibit potassium channels. Xib

conclusionsOur functional characterization of synthesized variants of xib

Indexed as

Potassium ChannelsAnimalsArthropod VenomsCyclic AMP-Dependent Protein KinasesEvolution, MolecularHumansMAP Kinase Signaling SystemMicePhylogenyArthropod VenomsCyclic AMP-Dependent Protein KinasesPotassium ChannelsElectrophysiologyHCI screeningICKKnottinMarine venomsVenomous crustaceansXibalbanusXibalbin1Xibalbin13Xibalbin2

Identifiers

PMID39075558
PMCPMC11288129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.